Drugs / MT-6345
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03809039 | Jan → Jul 2019 | — | Tanabe Pharma America, Inc. | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-6345 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03809039 ↗ |